Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pathogenic bacteria surface structures represent a broad category of extracellular and cell-envelope components that are critical for bacterial survival, pathogenesis, and host interaction [1]. These structures include the peptidoglycan cell wall, the outer membrane of Gram-negative bacteria (containing lipopolysaccharides), capsules, pili (fimbriae), and flagella [1, 3]. Biologically, they provide structural rigidity, facilitate motility, and enable the bacteria to adhere to host tissues or evade immune detection through mechanisms like antigenic variation or physical shielding [1]. Because many of these structures are unique to prokaryotes, they are primary targets for antimicrobial therapy; for example, beta-lactam antibiotics and glycopeptides like vancomycin target peptidoglycan synthesis, while polymyxins target the lipopolysaccharide (LPS) layer [2]. Furthermore, surface polysaccharides and proteins serve as the basis for many conjugate and recombinant vaccines, which prime the host immune system to recognize and neutralize specific pathogens [4]. However, the diversity and rapid evolution of these surface components present significant challenges, including the development of multi-drug resistance and the potential for systemic inflammatory responses, such as sepsis, upon the release of endotoxins during bacterial lysis [3]. Citations: [1] Silhavy, T. J., et al. (2010) Cold Spring Harb Perspect Biol. [2] Bush, K., & Bradford, P. A. (2016) Cold Spring Harb Perspect Med. [3] Ramachandran, G. (2014) Virulence. [4] Rappuoli, R. (2018) EMBO Mol Med.
Inhibition of cell wall peptidoglycan synthesis, disruption of the outer membrane or cytoplasmic membrane integrity, and induction of antibody-mediated opsonization or neutralization of surface antigens [2, 4].
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pathogenic bacteria surface structures.